Gujarat Themis Biosyn Ltd vs Procter Gamble Health Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Gujarat Themis Biosyn Ltd is ₹ 382.7 as of 05 May 15:30 . The p/e ratio of Gujarat Themis Biosyn Ltd changed from 62.8 to 48.7 over 5 quarters. This represents a CAGR of -18.41% The p/e ratio of Procter & Gamble Health Ltd changed from 52.5 to 0 over 9 quarters. This represents a CAGR of -100.00% The market cap of Gujarat Themis Biosyn Ltd changed from ₹ 3067 crore to ₹ 2877 crore over 5 quarters. This represents a CAGR of -4.99% The market cap of Procter & Gamble Health Ltd changed from ₹ 9285 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of -100.00% The revenue of Gujarat Themis Biosyn Ltd for the Dec '25 is ₹ 43.78 crore as compare to the Sep '25 revenue of ₹ 43.17 crore. This represent the growth of 1.41% The revenue of Procter & Gamble Health Ltd for the Dec '25 is ₹ 378.22 crore as compare to the Sep '25 revenue of ₹ 329.87 crore. This represent the growth of 14.66% The ebitda of Gujarat Themis Biosyn Ltd for the Dec '25 is ₹ 21.72 crore as compare to the Sep '25 ebitda of ₹ 21.76 crore. This represent the decline of -0.18% The ebitda of Procter & Gamble Health Ltd for the Dec '25 is ₹ 114.82 crore as compare to the Sep '25 ebitda of ₹ 125.22 crore. This represent the decline of -8.31% The net profit of Gujarat Themis Biosyn Ltd changed from ₹ 12.97 crore to ₹ 12.46 crore over 7 quarters. This represents a CAGR of -2.27% The net profit of Procter & Gamble Health Ltd changed from ₹ 46.56 crore to ₹ 77.59 crore over 7 quarters. This represents a CAGR of 33.89% The dividend payout of Gujarat Themis Biosyn Ltd changed from 14.97 % to 12.27 % over 5 quarters. This represents a CAGR of -14.71% The dividend payout of Procter & Gamble Health Ltd changed from 122.06 % to 0 % over 9 quarters. This represents a CAGR of -100.00% .

About Gujarat Themis Biosyn Ltd

Promoted byJayshree D Patel, Gujarat Themis Biosyn Limited (GTBL) was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Company commenced production in August 1985.
It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007. Initially manufacturing the antibiotic, erythromycin, GTBL obtained licences to manufacture bulk drugs like rifampicin, cephalexin, griseofulvin and their formulations in 1990.

About Procter & Gamble Health Ltd

Procter & Gamble Health Limited was erstwhile incorporated as E Merck (India) Limited in 1967.
The Company's name was changed from E Merck (India) Limited to Merck Limited on March 27, 2002.
Later, the name of the Company was changed to Procter & Gamble Health Limited on 6 May, 2019.
The company was set up to take over the business of the Indian branch of Emeda Exports with all their assets and liabilities.
The company is a 51% subsidiary of German firm Merck KGaA, is a leading player in vitamin formulations. Procter & Gamble Health Limited is an Indian-based company principally engaged in the business of manufacturing and marketing of pharmaceuticals and chemicals.

FAQs for the comparison of Gujarat Themis Biosyn Ltd and Procter & Gamble Health Ltd

Which company has a larger market capitalization, Gujarat Themis Biosyn Ltd or Procter & Gamble Health Ltd?

Market cap of Gujarat Themis Biosyn Ltd is 4,170 Cr while Market cap of Procter & Gamble Health Ltd is 8,566 Cr

What are the key factors driving the stock performance of Gujarat Themis Biosyn Ltd and Procter & Gamble Health Ltd?

The stock performance of Gujarat Themis Biosyn Ltd and Procter & Gamble Health Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Gujarat Themis Biosyn Ltd and Procter & Gamble Health Ltd?

As of May 5, 2026, the Gujarat Themis Biosyn Ltd stock price is INR ₹382.7. On the other hand, Procter & Gamble Health Ltd stock price is INR ₹5160.9.

How do dividend payouts of Gujarat Themis Biosyn Ltd and Procter & Gamble Health Ltd compare?

To compare the dividend payouts of Gujarat Themis Biosyn Ltd and Procter & Gamble Health Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.